Every 8-K that Adaptive Biotechnologies Corporation (ADPT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ADPT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ADPT filings page.
Adaptive Biotechnologies reported second quarter 2026 revenue of $71.6 million, up 22% from a year earlier, led by its Minimal Residual Disease (MRD) segment. MRD revenue reached $66.2 million, a 33% increase, while Immune Medicine revenue was $5.4 million, a 40% decrease, though up 8% excluding prior Genentech-related revenue. clonoSEQ test volume rose 43% to 36,111 tests. Adjusted EBITDA loss narrowed sharply to $0.7 million, compared with a $7.2 million loss in the prior-year quarter.
Net loss was $39.9 million, including a $23.7 million loss on extinguishment of a revenue interest liability tied to settling the OrbiMed Purchase Agreement; excluding this, net loss was $16.2 million. The company completed a $345 million zero-coupon convertible senior notes offering, repaid the OrbiMed obligation, and ended June 30, 2026 with $371.7 million in cash, cash equivalents and marketable securities. Full-year 2026 MRD revenue guidance was raised to $268–$278 million, and total operating expense guidance was set at $350–$355 million. Co-founder and Chief Scientific Officer Harlan Robins will transition to a strategic consultant role focused on MRD R&D and the planned separation of the Immune Medicine business; the company states there are no disagreements or performance issues related to his decision.
Adaptive Biotechnologies Corporation issued $345 million of 0% Convertible Senior Notes due 2031 in a private offering to qualified institutional buyers. The notes are senior unsecured obligations, carry no cash interest, and are convertible into common stock at an initial price of about $24.11 per share, a 40% premium to the June 16, 2026 share price of $17.22.
The company expects net proceeds of about $334.5 million, of which it used $156.9 million to repay in full its revenue interest obligations under the OrbiMed Purchase Agreement, $25.6 million to fund capped call transactions, and $25.0 million to repurchase 1,451,800 shares of common stock in privately negotiated transactions. The remainder will support general corporate purposes and initiatives in its minimal residual disease (MRD) business. Capped call transactions with a cap price of $34.44 per share are designed to reduce potential dilution or excess cash payments upon conversion, subject to limitations.
Adaptive Biotechnologies plans a private offering of $250 million in convertible senior notes due 2031, with an option for an additional $37.5 million, and intends to use proceeds for capped call transactions, up to $25 million of share repurchases and repayment of its OrbiMed revenue interest agreement.
The company is also pursuing a separation of its Minimal Residual Disease (MRD) and Immune Medicine businesses, aiming to choose a preferred path by year-end 2026. MRD has grown revenue from $103 million in 2023 to $212 million in 2025 and reported $15 million of 2025 adjusted EBITDA, while Immune Medicine has built a large immune-receptor dataset and discovery platform.
Adaptive Biotechnologies Corporation reported the results of its annual shareholder meeting held on June 5, 2026. Shareholders voted on electing two Class I directors, an advisory say-on-pay proposal, and ratifying the independent auditor.
Robert Hershberg received 93,188,652 votes for, or 71.81% of votes on the proposal, with 36,573,708 votes withheld and 13,570,859 broker non-votes. Katey Owen received 126,803,695 votes for, or 97.72%, with 2,958,666 votes withheld and the same broker non-votes.
The advisory vote on 2025 named executive officer compensation passed with 125,287,618 votes for (96.55%), 4,316,144 against, and 158,599 abstentions, plus 13,570,859 broker non-votes. Ratification of Ernst & Young LLP as independent registered public accounting firm for 2026 passed with 142,609,643 votes for (99.50%), 484,798 against, and 238,779 abstentions.
Adaptive Biotechnologies reported strong first quarter 2026 results driven by its Minimal Residual Disease (MRD) business. Revenue was $70.9 million, up 35% from the prior-year quarter, with MRD revenue of $67.1 million, a 53% increase. Immune Medicine revenue was $3.8 million, down 57%, reflecting lower Genentech-related activity.
Net loss improved to $20.0 million from $29.8 million, and Adjusted EBITDA loss narrowed to $2.5 million from $12.7 million. The company ended March 31, 2026 with $237.2 million in cash, cash equivalents and marketable securities and raised full-year 2026 MRD revenue guidance to $260–$270 million, implying 22–27% annual growth.
Adaptive Biotechnologies Corporation furnished an update on its financial performance by issuing a press release covering results for the quarter and fiscal year ended December 31, 2025. The company submitted this current report to make that earnings release available to investors and attached it as Exhibit 99.1.
The press release with detailed financial figures and commentary is incorporated by reference but is expressly treated as "furnished" rather than "filed" under securities laws, which affects how it is used in certain legal contexts and other regulatory filings.
Adaptive Biotechnologies Corporation reported that it issued a press release with its financial results for the quarter and year ended December 31, 2025. The press release, dated January 12, 2026, is furnished as Exhibit 99.1 to this report. The company also furnished an investor presentation, dated the same day, as Exhibit 99.2, which management may use in meetings with investors and analysts. Both the earnings release and the presentation are being furnished rather than filed, meaning they are not automatically incorporated into other securities law filings unless specifically referenced.
Adaptive Biotechnologies (ADPT) furnished an 8-K announcing it issued a press release with financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference as stated therein.
The company notes the information provided under Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed “filed” under the Exchange Act, nor incorporated into Securities Act or Exchange Act filings except by specific reference.
Adaptive Biotechnologies Corporation disclosed developments focused on its Immune Medicine initiatives. The filing notes work on TCR-antigen prediction models to enable new immunology applications and partnerships, and progress toward a pre-clinical data package for its lead T-cell depletion program in autoimmunity. The company also states a fiscal year 2025 Immune Medicine cash burn target of $25–$30 million. The filing references recognition of non-cash revenue from remaining amortization of cash consideration under an agreement. The document is dated August 18, 2025.